<DOC>
	<DOCNO>NCT00416520</DOCNO>
	<brief_summary>This phase III multi-centre study three period : first period phosphate binder washout 4 week , second period open-label , randomise , parallel group , flexible dose , third period placebo-controlled withdrawal compare MCI-196 placebo 4 week .</brief_summary>
	<brief_title>A Phase III , Multicentre , Double-Blind , Placebo-Controlled Withdrawal Study Patients With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Male female , 18 year age Clinically stable haemodialysis peritoneal dialysis Stable phosphate control On stabilised phosphorus diet Female childbearing potential negative serum pregnancy test . Male subject must agree use appropriate contraception . Current clinically significant medical comorbidities , may substantially compromise subject safety , expose undue risk , interfere significantly study procedure , opinion Investigator , make subject unsuitable inclusion study . Body Mass Index ( BMI ) &lt; =16.0 kg/m2 &gt; =40.0 kg/m2 A current history significant gastrointestinal motility problem A positive test HIV 1 2 antibody A history substance alcohol abuse within last year . Seizure disorder A history drug allergy A temporary catheter vascular access Participated clinical study experimental medication last 30 day experimental biological product within last 90 day prior sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Phosphate binder</keyword>
</DOC>